IMR Press / EJGO / Volume 23 / Issue 6 / pii/2002227

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Prognostic significance of DNA Topoisomerase II-α (Ki-S1) immunoexpression in endometrial carcinoma

Show Less
1 Department of Pathology, Gynecologic Oncology Unit, Osmangazi University School of Medicine, Turkey
2 Department of Obstetrics and Gynecology, Gynecologic Oncology Unit, Osmangazi University School of Medicine, Turkey
3 Department of Statistics, Faculty of Arts and Sciences, Osmangazi University, Eskisehir, Turkey
Eur. J. Gynaecol. Oncol. 2002, 23(6), 540–544;
Published: 10 December 2002

Objective: In order to determine the significance of proliferative activity (PA) in endometrial carcinomas, we analysed the expres­sion of cell cycle-related antigens in routinely processed tissue. Materials and Methods: Serial sections of 113 endometrial carcinoma specimens were immunostained with the monoclonal anti­body DNA Topoisomerase II-α (Ki-S1). In addition to Topoisomerase II-α (Ki-S1) staining, histologic type, International Federa­tion of Gynecology and Obstetrics (FIGO) stage, FIGO grade, depth of myometrial invasion, tumor size, lymphovascular space inva­sion, serosal and/or adnexal involvement, lymph node metastasis, age and peritoneal cytology were evaluated as prognostic indicators. The median follow-up time was 23 (range, 1 to 126) months. Results: FIGO stage, FIGO grade, tumor size, lymphovascular space invasion, lymph node metastasis, peritoneal cytology and Topoisomerase II-α (Ki-S1) expression all significantly influenced survival in univariate analyses (≤0.05). In the Cox regression analysis, Topoisomerase II-α (Ki-S1), serosal and/or adnexal involvement, and lymph node metastasis expression were the only varia­bles with independent prognostic impact (≤0.05), whereas FIGO stage, FIGO grade, histologic type FIGO grade, depth of inva­sion, tumor size, lymphovascular space invasion, age and peritoneal cytology had no independent influence (p > 0.05). Topoisome­rase II-α (Ki-S1) staining was significantly elevated in advanced (Stage II, III, IV) as opposed to early (Stage I) carcinomas (≤0.05). Conclusion: The association with established prognosticators for endometrial carcinomas, and the results of uni- and multivariate analysis indicate that the additional evaluation of DNA Topoisomerase II-α (Ki-S1) peptide antibody (PA) is useful for classifying patients into subgroups with low and high risk of relapse which might help to individualize the therapeutic strategy in endometrial carcinomas.

Endometrial carcinoma
DNA Topoisomerase II-α
Monoclonal antibodies
Back to top